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Abstract Clinical metabolomics has emerged as a powerful
tool to study human metabolism in health and disease.
Comparative statistical analysis of untargeted metabolic pro-
files can reveal perturbations of metabolite levels in diseases
and thus has the potential to identify novel biomarkers. Here
we have applied a simultaneous genetic-metabolomic ap-
proach in twin boys with epileptic encephalopathy of unclear
etiology. Clinical exome sequencing identified a novel mis-
sense mutation in the spermine synthase gene (SMS) that
causes Snyder-Robinson syndrome (SRS). Untargeted plasma
metabolome analysis revealed significantly elevated levels of
N8-acetylspermidine, a precursor derivative of spermine bio-
synthesis, as a potential novel plasma biomarker for SRS. This
result was verified in a third patient with genetically con-
firmed SRS. This study illustrates the potential of
metabolomics as a translational technique to support exome
data on a functional and clinical level.
Introduction
Mass spectrometry (MS) based screening for biomarkers of
inborn errors of metabolism (IEM) is now routine and applied
in newborn screening programs as well as in selective work-
up of IEM (Chace 2001). MS-based metabolomics represents
a comprehensive, quantitative and simultaneous analysis of all
small molecule metabolites in a defined biofluid and thus re-
flects its distinct metabolic composition (Patti et al 2012;
Moco et al 2013). Recent advances in instrumental and com-
putational technologies have enabled clinical metabolomics to
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emerge as a powerful tool for the identification of novel bio-
markers and distinct metabolic profiles in IEM (Wikoff et al
2007; Shlomi et al 2009; Moco et al 2013).
Snyder-Robinson syndrome (SRS) is a rare X-linked reces-
sive disorder. By linkage analysis the disease-causing gene
was mapped to the chromosomal region Xp.21.3-p22.12, har-
boring the spermine synthase gene (SMS) with first mutations
identified in 2003 (Cason et al 2003). Spermine is a polyamine
that is involved in several key cellular processes including
proliferation, protein and nucleic acid synthesis, cell adhesion
and signaling and ion channel regulation (Pegg and Michael
2010). Spermine synthase (SMS; EC: 2.5.1.22) converts
spermidine to spermine and belongs to a group of
aminopropyltransferases (Pegg and Michael 2010; Sowell
et al 2011) (Fig. 1).
SRS is characterized by moderate to severe intellectual dis-
ability, unsteady gait, and hypotonia (Snyder and Robinson
1969). To date, only four families with SRS have been de-
scribed, indicating that the syndrome is either very rare or
underdiagnosed. Reevaluation of the original and novel fami-
lies led to the delineation of a syndromic phenotype addition-
ally characterized by facial dysmorphism, asthenic body build,
bone abnormalities including osteoporosis and kyphoscoliosis,
nasal dysarthric, coarse, or absent speech, high or cleft palate,
urogenital abnormalities, mild short stature and seizures
(Arena et al 1996; Cason et al 2003; de Alencastro et al
2008; Becerra-Solano et al 2009; Peron et al 2013).
Here, we report the identification of N8-acetylspermidine
as a potential novel plasma biomarker for spermine synthase
deficiency through untargeted plasma metabolomics analysis
of twin boys and a further unrelated previously published
patient (Peron et al 2013).
Clinical report
The male monozygotic twins were delivered by cesarean sec-
tion at 37 5/7 gestational week after a 1st uncomplicated preg-
nancy of healthy, non-consanguineous parents. Apgar scores
were 8-8-9 in both. Birth weight, length and head circumfer-
ence were below the 3rd percentile in both twins.
Cytomegalovirus (CMV) PCR from the newborn blood spot
screening was negative in twin A, while the card could not be
analyzed in twin B for technical reasons. In twin B, CMV
PCR in urine was positive. However, no other evidence for
connatal CMV infection was found, including normal oph-
thalmological findings. Brain stem audiometry at the age of
4 months was normal in twin A and revealed a mild conduc-
tion defect in twin B. Behavioral observation audiometry was
normal in twin B at age 2 years. Early development was de-
layed and both twins presented with axial hypotonia and mus-
cular hypertonia of the lower extremities. Dysmorphic fea-
tures became more apparent during the second year of life.
At the age of 12 months, recurrent irregular myoclonic jerks
were observed in both twins and serial infantile spasms in twin
A. Twin B showed photosensitivity with myoclonic jerks,
twin A had hypsarrhythmia in sleep and serial spasms at
awakening.Myoclonic seizures were drug-refractory and both
Fig. 1 Polyamine biosynthesis and conversion pathway, highlighting selected metabolites discussed in the text
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boys suffered additional atonic and tonic seizures as well as
atypical absences in the further course. At the age of
15 months, along with recurrent respiratory infections, they
developed a severe encephalopathy with frequent seizures and
developmental regression with reduced social and visual in-
teraction. From the age of 17 months both twins developed a
distinct choreo-athetotic movement disorder that gradually
improved over the following 6 months. At the age of
23 months, twin B suffered from non-traumatic left-sided
clavicular fracture, both showed osteopenia. At the last
clinical exam at the age of 29 months, development was
severely affected with absence of speech, active sitting,
and grasping. Both boys still suffered from generalized
myoclonic jerks and asymmetric tonic seizures and displayed
abnormal EEGs.
Head circumference was −2.9 SD in both with plateauing
of head growth since the age of 18 months. Magnetic reso-
nance imaging of the brain at age 13 (twin A) and 14 months
(twin B) respectively, showed a thin corpus callosum and
slight cerebral atrophy in twin A, while twin B had isolated
bilateral pallidal hyperintensity. Screening tests for metabolic
diseases were all normal (details in Supplementary material).
Details on the clinical course are given in the Supplementary
material.
Methods and materials
Parents of all three patients had given full written informed
consent for participation in a study on metabolic-genetic re-
search into early onset epileptic encephalopathies (EE) and a
metabolome study, respectively. Both studies have been ap-
proved by the Institutional Review Board of the Kanton of
Zurich. The plasma sample of the third SRS patient was sub-
mitted upon specific request. Control samples included seven
patients (age range 1.5–13.5; mean 7.7±5.87, median
9.2 years) from the abovementioned EE study cohort in which
exome sequencing revealed disease-causing mutations other
than SMS or were inconclusive. We further included six age-
and sex-matched and six sex-matched healthy controls of sim-
ilar age (range 32–45 months; mean 40±4.8; median
41 months).
Reagents
All reference compounds, ultra LC-MS grade solvents and
reagents for the metabolomics analysis were purchased from
Sigma-Aldrich AG (Buchs, Switzerland).
Genetic studies
Genomic DNA was extracted from EDTA blood. Zygosity
testing was performed using the PowerPlex™ 16
microsatellite kit (Promega Inc.) in both twins. High resolu-
tion copy number profiling was performed with the
CytoscanHD microarray (Affymetrix Inc.). Targeted exome
sequencing on 4813 known disease genes was performed
using the TruSight™ One Sequencing Panel (4813 Genes,
Illumina Inc.) with paired-end sequencing (MiSeqReagent
Kit v3, 200 Fwd-200 Rev) on a MiSeq System (Illumina
Inc.). Filtering of variants is described in Supplementary ma-
terial. The candidate SMS variant was confirmed and tested
for segregation by Sanger sequencing. Maternal X-
chromosome inactivation pattern at the androgen receptor
was investigated as described (Lau et al 1997).
Metabolomics data acquisition and preprocessing
Samples were analyzed by liquid chromatography-mass spec-
trometry (LC-MS; Dionex Ultimate XRS3000 UHPLC
coupled to a Q-Exactive high resolution, accurate mass spec-
trometer (Thermo Scientific, Sunnyvale, CA, USA)).
Chromatographic separations were achieved using a 2.1×
100 mm Kinetex HILIC column (Phenomenex, Torrance,
CA, USA). Mobile phases used were: A) 50 % acetonitrile
in 5 mM ammonium formate (pH 3.0), and B) 90 % acetoni-
trile in 5 mM ammonium formate (pH 5.0). Total run time was
15 min with a 10 min linear gradient running from 100 % B to
100 % A. Solvents were pumped at 400 μL/min, with a col-
umn temperature of 30 °C and sample chamber held at 5 °C.
Mass spectrometric measurements were acquired in positive
and negative ionization modes through the heated electro-
spray ionization (HESI) source.
The untargeted metabolomics data set was acquired with
the MS detector in full-scan mode (Full-MS) with data-
dependent (dd-MS2) acquisition of fragment ions from the
top-5 most abundant ions per scan. Detector settings can be
found in the Supplementary material.
Data were collected in Xcalibur (Thermo) and preprocess-
ing was performed in R (x64, v3.1.0) the free software envi-
ronment for statistical computing and graphics (http://www.r-
project.org/). Feature detection and retention time correction
were done using XCMS (Smith et al 2006; Tautenhahn et al
2008). Peak list annotation was done in CAMERA (Kuhl et al
2012). All data features of interest were manually inspected
for peak shape and alignment, and then mined against the
Metlin database (Smith et al 2005) and the Human
Metabolome Database (http://www.hmdb.ca/). Date of the
last database access was March 27, 2015 for both Metlin
and HMDB.
Statistical analysis
Data pretreatment included 1) noise filtering and missing val-
ue imputation, where negative data values or features missing
from at least 80 % of data were eliminated 2) data
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normalization, achieved by calculating the sum of all variables
within a spectrum and by factoring each spectral sum to a
value of 1. Each variable is then transformed as a fraction of
the total spectral sum. All data preprocessing, data scaling
(e.g., pareto) and univariate analysis were performed in R
utilizing the MUMA package (Gaude et al 2013).
Multivariate data analysis was performed by SIMCA v13.0.3
(Unimetrics,Malmö, Sweden). Data matrices containingmass
over charge (m/z), and normalized ion signal intensity were
analyzed with the unsupervised principle components analysis
(PCA; Figure S1). Orthogonal projection to a latent structure-
discriminant analysis (OPLS-DA) was used to evaluate and
rank the differential metabolite expression profiles (Table S1
and Supplementary material). Relative metabolite ratios were
calculated by comparing the integrated area under curve for
the target metabolite. Receiver operating characteristic (ROC)
analysis and false-discovery rates were calculated in
GraphPad Prism 6 (Fig. S2; GraphPad Software Inc.)
Determination of polyamine ratios
Samples
Lymphoblast cell cultures were established from patient
EDTA-blood according to standardized protocols. Patient
lymphoblasts were grown in Gibco RPMI-1640 Media-
20 % FBS, 1 % antibiotic/antimycotic in a 10 % CO2 regu-
lated incubator with humidity. Cultures were pelleted by cen-
trifugation at 150×g for 3 min, washed in ice cold phosphate
buffered saline and centrifuged at 150×g for 3 min. The cell
pellets were suspended in 500 uL of 0.1 % formic acid in
methanol, sonicated for 5 min and centrifuged at 20,000×g
for 15 min at 4 °C. The supernatant was aspirated into a clean
tube and dried under reduced atmosphere. The resultant or-
ganic fraction was resolved in 10 % acetonitrile in ultra-grade
water with 0.1 % formic acid (FA) and 0.02 %
heptafluorobutyric acid (HFBA).
LC-MS analysis of polyamine ratios
Analysis of the spermine/spermidine ratio was done according
to published methods with minor modifications (Sowell et al
2011). Chromatography was performed on a Thermo
Scientific Dionex Ultimate XRS 3000 UHPLC system using
a C8 column (Supelco Ascentic Express C8 2.1×100 mm) at
30 °C. A 5 μL injection volume was used for analysis with a
solvent system consisting of mobile phase A (0.1 % FA and
0.02 % HFBA in water), and mobile phase B (0.1 % FA and
0.02 % HFBA in acetonitrile). Spermine and spermidine were
separated using a linear gradient of 10 to 40%mobile phase B
over 10 min with a flow rate of 0.3 mL/min. Mass spectro-
metric data were acquired on a Thermo Scientific Q-Exactive
Orbitrap operating in positive ionization mode.
Results
Genetic analysis
Targeted exome sequencing in twin A covered about 95 % of
the targeted region with ≥20 independent sequence reads and
revealed a total of 105 private non-synonymous coding and
splice site variants in known disease genes. After filtering of
the variants found, four candidate variants were further inves-
tigated by Sanger sequencing (SOS1 (p.Leu356Ile); SPTAN1
( c . 2 3 8 - 9C > T ) ; SMS ( p .A rg 1 3 0Cy s ) ; EFHC1
(p.Phe229Leu)). While the autosomal variants in SOS1,
SPTAN1, and EFHC1 were found inherited from the healthy
father and thus considered likely benign, the hemizygous mis-
sense mutation within exon 5 of the X-linked spermine syn-
thase gene (SMS: c.388C>T (p.Arg130Cys); hg19
chrX:21995237;) was compatible with X-linked recessive in-
heritance and was shown to be inherited from the healthy
mother. The mutation was absent in both maternal grandpar-
ents and thus likely occurred de novo in the carrier mother.
Maternal X-inactivation in blood was found to be mildly
skewed, with one allele active in 83 % of the cells and the
other allele in 17 %. Since the mother is a healthy carrier, we
assume that the wild-type allele is preferentially active. The
mutationwas not reported previously and affects an evolution-
ary conserved amino acid. Moreover, five of six applied in
silico programs predicted a deleterious effect of the SMS mu-
tation (SIFT: score 0 (damaging); PhyloPhen: score 0.9990/
0.7180 (D probably damaging/P possibly damaging); LRT:
score 0 (deleterious); Mutation taster: score 1 (disease caus-
ing); Mutation assessor: score 2.325 (medium → predicted
functional); FATHMM: score −0.6300 (tolerated, values low-
er than −1.5 are predicted as damaging). Information on the
SMS mutation modeling is included in the Supplementary
material and in Fig. S3.
Metabolomics analysis
The details of the metabolomics data preprocessing can be
found in the Supplementary material. PCA of the resultant
data matrix revealed differential clustering of the SRS cohort
against the control cohort with 97 % of the variation within
the training set explained by the model and 90 % of the
variation in the training set predicted by the model according
to cross validation in the 26th component (R2X (cum)=0.97;
Q2 (cum)=0.90). Application of supervised OPLS-DA
allowed a detailed differential expression analysis between
the SRS and control cohorts (R2X (cum)=0.71; R2Y
(cum)=0.99; Q2 (cum)=0.99). An overall false-discovery
rate (FDR) of 0.01 was calculated by an empirical Bayesian
method based on moderated t-statistics (Schwender and
Ickstadt 2008).
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Spermine to spermidine ratio and spermine synthase
deficiency
Calculation of the ratio of spermine to spermidine ratio in
cultured lymphoblasts derived from twin A and B gave values
of 0.02 and 0.05, while the ratio was 0.12 and 0.10 in two
controls respectively. These values are indicative of a deficien-
cy in spermine synthase and correspond to those previously
established for SRS (Sowell et al 2011). The Western blot
analysis of cell lysates in the twin brothers further demonstrat-
ed the absence of spermine synthase thus confirming the di-
agnosis on a protein level (Fig. S4).
N8-acetylspermidine as a novel potential biomarker
for Snyder-Robinson syndrome
The results of the discriminant analysis (OPLS-DA; Table S1)
identified several compounds directly corresponding to poly-
amine metabolism in the SRS patient plasma samples: N8-
acetylspermidine, spermidine, isoputreanine and ornithine
(Figs. 2 and 3). Identification of N8-acetylspermidine was
confirmed by comparison of accurate-mass signal
(C9H21N3O cal’d [M+H] 188.17574; Obs. 188.17526 Δ
ppm 2.4), retention time and MS/MS fragmentation pattern
with that of commercially available reference material
(Figs. S5 and S6). Integration of the area under curve for this
ion peak revealed a greater than threefold relative increase in
the SRS samples versus the control samples (Fig. 3).
Statistical significance was confirmed by receiver operating
curve (ROC) analysis (Fig. S2).
Discussion
SRS is a rare X-linked disorder that was hitherto diagnosed by
molecular analysis of the SMS gene and/or analysis of the
spermine/spermidine ratio in patient lymphoblasts based on
an LC-MS/MS assay (Sowell et al 2011). By means of a
non-targeted metabolomics approach, we were able to identify
a novel potential plasma biomarker for SRS which requires a
single blood plasma sample. Rigorous statistical analysis of
the global metabolomics data revealed several significantly
altered metabolites involved in spermine/spermidine metabo-
lism (Table S1). Among them, the peak intensity of N8-
acetylspermidine was significantly higher in the twin patients
and a third unrelated SRS patient (Peron et al 2013) compared
to 19 controls. Spermine synthase deficiency leads to accumu-
lation of spermidine that is converted to N8-acetylspermidine
and exported from the cell. Isoputreanine results from conver-
sion of N-acetylspermidine and serves as a precursor for 4-
aminobutyric acid (GABA), the most important inhibitory
neurotransmitter. The function of spermine and spermidine
in SRS disease etiology is not yet fully elucidated, but it might
be speculated that the altered spermine/spermidine ratio may
severely affect the balance between excitatory and inhibitory
mechanisms and result in cerebral dysfunction such as epilep-
sy. Spermine and spermidine regulate brain glutamate recep-
tors including N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
kainate receptors that are involved in excitatory synaptic trans-
mission (Pegg 2009; Igarashi and Kashiwagi 2010). Spermine
Fig. 2 Box plots for spermidine, isoputreanine, and ornithine showing
significant relative variation (p<0.001) between control (blue) and SRS
(red) plasma samples. Data for each sample was acquired in technical
triplicate with three longitudinal samples (July/December 2014,
February 2015) collected for SRS twins. All three metabolites
correspond to the polyamine metabolic pathway given in Fig. 1. ****
indicates p-value<0.001
Fig. 3 Box plots showing normalized N8-acetylspermidine ion
intensities for controls (n=19) and SRS samples with longitudinal
sample collection for SRS twins A and B (n=9). Data for each sample
was acquired in technical triplicates. **** indicates p-value<0.001
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activates the endogenous phosphorylation and function of the
GABAA receptor (SidAhmed-Mezi et al 2010). It was shown
that GABAA receptor phosphorylation is significantly re-
duced in epileptogenic human tissue (SidAhmed-Mezi et al
2010). Spermidine itself mediates pro-epileptic effects by in-
creased NO-synthesis in an experimental rat model
(Stojanovic et al 2010). Furthermore both spermine and
spermidine are potent blockers of voltage-gated Na+ channels
and their pharmacological depletion leads to increased epilep-
togenic activity in pyramidal neurons (Fleidervish et al 2008).
Modulation of NMDA receptors was further implicated in the
etiology of intellectual disability (Igarashi and Kashiwagi
2010; Pegg 2014). Other SRS phenotypic aspects such as
osteoporosis and deafness are explained by the involvement
of spermine and spermidine in the regulation of osteoclastic
activity and endocochlear potential homeostasis (Wang et al
2009; Yamamoto et al 2012).
In our twin patients, the diagnosis of SRS was confirmed
by clinical exome sequencing. The mutation Arg130Cys was
not described previously and is predicted to diminish enzy-
matic activity by decreasing dimer stability and affecting the
structure of the adjacent spermine binding site. The phenotyp-
ic aspects of our patients match those of previously published
SRS patients. However, some of the typical features including
dysarthric speech and movement disorder may only evolve
with age and thus hamper a timely diagnosis (de Alencastro
et al 2008; Kesler et al 2009; Peron et al 2013). Peron et al.
recently described a patient with SRS and onset of
hypsarrhythmia at the age of 1 year (Peron et al 2013). The
phenotype of our patients with early onset epileptic encepha-
lopathy further expands the clinical spectrum and confirms
that early-onset myoclonic seizures may represent a cardinal
feature of those SRS patients presenting with epilepsy as sug-
gested by Peron et al (2013).
In summary, we provide evidence for a potential novel
plasma biomarker in SRS and report on the pathogenicity of
a novel Arg130Cys mutation in SRS by a combined multi-
omics approach. This study illustrates the potential of meta-
bolomics as a translational technique to support exome data
on a functional and clinical level.
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